vTv Therapeutics (NASDAQ:VTVT) Stock Bumped Down to Sell by Wall Street Zen

Key Points

• Wall Street Zen downgraded vTv Therapeutics from “hold” to “sell,” adding a bearish view to a mixed analyst outlook.
• Despite the downgrade, the stock retains a consensus “Moderate Buy” rating, with one Strong Buy, six Buy, one Hold and one Sell recommendation; the average price target is $55.83.
• vTv shares opened at $25.55, down 5.9%, while the company reported a quarterly loss of $1.05 per share—worse than the $0.97 consensus estimate.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Saturday, Wall Street Zen reports.

Other analysts have also issued reports about the company. Zacks Research raised vTv Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday, September 7th. Rodman & Renshaw began coverage on vTv Therapeutics in a report on Tuesday, June 30th. They set a "buy" rating and a $67.00 price objective for the company. Lifesci Capital raised vTv Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 2nd. Weiss Ratings lowered shares of vTv Therapeutics from a "sell (d+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Finally, BTIG Research reissued a "buy" rating and issued a $57.00 price objective on shares of vTv Therapeutics in a report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $55.83.

vTv Therapeutics Stock Down 5.9%

NASDAQ:VTVT opened at $25.55 on Friday. The stock's 50 day moving average price is $30.95 and its 200 day moving average price is $32.90. The company has a market capitalization of $100.64 million, a PE ratio of -24.10 and a beta of 0.21. vTv Therapeutics has a 52-week low of $19.50 and a 52-week high of $44.00.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.08). As a group, sell-side analysts anticipate that vTv Therapeutics will post -2.35 EPS for the current fiscal year.

About vTv Therapeutics

vTv Therapeutics, Inc NASDAQ: VTVT is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company's research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer's disease.

vTv's development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.